Sections

Alphabetical list:

A B C D E F G H I J K L M N O P R S T U V W X Y Q Z 1 2 3 4 5 6 7 8 9

News: November 29, 2009

Rituximab May Offer Hope To Severe Graves' Eye Disease Patients

November 29, 2009

There may be hope for patients with severe Graves' eye disease in the form of treatment with the drug rituximab.

This news comes from U-M Kellogg Eye Center who's oculoplastics specialist Raymond S. Douglas, M.D., Ph.D. reports on the potential of the drug in the online October issue of Ophthalmology.

Graves' eye disease is an autoimmune disease that causes inflammation and fatty deposits in the eye muscles and connective tissue surrounding the eye.

Douglas reports on the progress of six patients (four women, two men) who had not responded to treatment using systemic corticosteroids. The patients were then treated with rituximab. All patients responded within 2 months with the clinical activity score (CAS) improving from5.50.8 to 1.30.5. The eye disease remained quiescent in all with the positive results being sustained at 4-6 months after treatment.

Vision improved bilaterally in all 4 patients with dysthyroid optic neuropathy (DON). Proptosis remained stable (Hertel measurement, 243.7 mm before therapy and 23.63.7 mm after therapy; P = 0.17).

"These patients had already received the maximum level of steroid treatment," says Douglas. "Treatment with rituximab calmed inflammation, stopped progression of the disease, and saved the patients from having to undergo surgery."

Graves' disease (also known as thyroid eye disease) is an autoimmune condition in which white blood cells attack the thyroid gland which responds by secreting an excess amount of thyroid hormone. The hypermetabolic state is characterized by fast pulse/heartbeat, palpitations, profuse sweating, high blood pressure, irritability, fatigue, weight loss, heat intolerance, and loss of hair and alterations in hair quality.

Rituximab has been used to treat patients with other autoimmune diseases, including rheumatoid arthritis and in non-Hodgkin's B-cell lymphoma. The drug works by depleting B cells - the body's normal antibody-producing cells - that appear to go awry in autoimmune diseases.

"Treatment of the inflammatory component of Graves' eye disease has not advanced appreciably over several decades," says Douglas. High-dose steroids, sometimes in combination with orbital radiation, are still the first line treatment. But, says Douglas, "These are imperfect options because inflammation often recurs when the treatment ends." He is hopeful that rituximab can offer sustained improvement. Douglas observes that the results from a small case series must be viewed with some caution. But given the substantial benefits for patients treated with rituximab, he sees good reason to proceed with a large-scale clinical trial to test this promising new drug.

Source

Rituximab Treatment of Patients with Severe, Corticosteroid-Resistant Thyroid-Associated Ophthalmopathy; Ophthalmology, 2009; Chong et al.; DOI: 10.1016/j.ophtha.2009.05.029


University of Michigan Health System Newsroom



Archive issues: (50)

Archive list: 1 [2] 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

December 12, 2009 | Researchers Find New Drug To Shrink Breast Cancer Tumors

Boston (SmartAboutHealth) - Researchers have discovered a new antibody drug that has the ability to shrink breast cancer tumors that other drugs have failed to impact.  The study was carried out ...

December 11, 2009 | Fewer dollars for smoking prevention

Even as states pull in billions of dollars in tobacco settlement money - part of which is typically used to fund anti-smoking programs - they're slashing the amount they spend on such programs by 15%.   Altogether, states will spend $567.5 million on anti-smoking efforts in the 2010 fiscal year, says a report released by five ...

December 9, 2009 | Smoking Kills Millions Worldwide Every Year

Tobacco use kills at least 5 million people every year, a figure that could rise if countries don't take stronger measures to combat smoking, the World Health Organization said Wednesday.  In a new report on tobacco use and ...

Archive list: 1 [2] 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related articles:

Alternative treatment methods

  Numerous alternative therapies are used to improve sexual function. Some include: niacin, zinc, copper, Korean red ginseng root, ginkgo, pine bark, Tribulus terrestris, arginine, Avena sativa, horny goat weed, maca root, muira puama, saw palmetto, and Swedish flower pollen. None of these however have ...

Section: Erectile Dysfunction

Treatment - medication (pentosan polysulfate)

  Oral pentosan polysulfate (Elmiron) is believed to provide a protective coating in the bladder, but studies show it is not statistically significant compared to placebo. However, some studies have found that a minority of patients do respond to pentosan polysulfate.    

Section: Interstitial cystitis

Stoicism and emotional repression

  Society has different rules with regards to the way that men and women are supposed to express themselves. Men are generally regarded as the ones who are supposed to give comfort and strength. If they break down, cry, or seek comfort they may lose face. Women and other men do not give men an option to express feeling sad, tired, weak, depressed, inadequate, needy, or lonely without sacrificing their ...

Section: Mens health risks

News

December 20, 2009

Wii, Xbox 360 and Other Video Games Offer Some Benefits

Wii, Xbox 360, PlayStation, and other video games are hot on holiday gift lists, but some parents wonder whether these games offer any benefits or are detrimental to kids. The results of a new study may put some minds at ease, while others may not.  According to the findings reported in the ...

December 18, 2009

Should You Be Shoveling Snow?

Yes, the weather outside is frightful, and soon you will have to think about shoveling snow. But should you be the one doing the work? Who should and should not shovel snow, and how can you do it safely?  Every winter, approximately 1,200 Americans die from a heart attack or another ...

December 17, 2009

Athletes who take NSAID's to prevent pain may be doing more harm than good

According to Stuart Warden, a researcher who studies musculoskeletal health and sports medicine, athletes who ritualistically take NSAID's to prevent post event and workout soreness and inflammation may be depriving the body of healing, in addition to risking other ...

Blogroll